Lyssikatos Joseph P's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jan 12, 2026
- Accession no.
- 0001967150-26-000001
- Filed
- Jan 12, 2026
- Trade date
- Jan 8-9, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions. Open-market sales total $3.48M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lyssikatos Joseph PCIK 0001967150 | Officer (CHIEF SCIENTIFIC OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Common Stock | SSaleDisposed | −7,500 | $20.13F2 | −$150,975 | 890,188 | Indirect | |
| Jan 8, 2026 | Common Stock | SSaleDisposed | −33,802 | $24.92F4 | −$842,345.84 | 856,386 | Indirect | |
| Jan 9, 2026 | Common Stock | SSaleDisposed | −41,198 | $24.90F5 | −$1,025,830.2 | 815,188 | Indirect | |
| Jan 9, 2026 | Common Stock | SSaleDisposed | −50,000 | $29.13F6 | −$1,456,500 | 765,188 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.